Mitigating the Impact of Influenza: Treatment and Prophylaxis
Claim Credit
Claim Credit
Mitigating the Impact of Influenza: Treatment and Prophylaxis
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
0.75 CME
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Mitigating the Impact of Influenza: Diagnostic Challenges
Claim Credit
Claim Credit
Mitigating the Impact of Influenza: Diagnostic Challenges
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
0.50 CME
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Subscribe
ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
Back to Healio
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors
By
Staff
58 seconds ago
NEW YORK–(BUSINESS WIRE)–#EYEN Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulato
Illustrative image of cancer cells (Design Cells; iStock by Getty Images)
KAHR, a maker of cancer immunotherapies, said it has entered into an exclusive licensing agreement with Thomas Jefferson University in Philadelphia to develop and commercialize a number of new cancer drug candidates.
Under the agreement, the university is granting KAHR the license to develop and commercialize new immuno-oncology drug candidates based on fusion proteins. These drugs are complex structures made by fusing the natural sequence of different proteins to make them bind two or three targets on cancer and immune cells. The new drug candidates entering development are called DSP502 (TIGITxPD1) and DSP216 (LILRB2xSIRPa).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Inozyme Pharma Expands its Scientific Advisory Board
Inozyme Pharma Inc.April 1, 2021 GMT
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications:
W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine